



Holista Colltech Limited
(ASX:HCT / ABN 24 094 515 992)
283 Rokeby Road Subiaco WA 6008
P: +61 412 474 180
W: www.holistaco.com

Appendix 4C and Activities Report: ProlImmune Settlement; Continued Focus on Cash Management

ASX Announcement

30 July 2026

Holista Colltech Limited (ASX: HCT, “Holista” or “the Company”) is pleased to provide the following update on its operational and financial performance for the quarter ended 30 June 2026, together with the accompanying Appendix 4C.

Key Highlights

- Group revenue was approximately \$1.50 million, representing a 0.8% increase compared with the previous quarter.
- Customer receipts increased 12.9% to approximately \$1.48 million, driven by improved collections, debt recoveries and deposits received.
- During the quarter, the Company paid the first tranche of US\$1.0 million under the ProlImmune legal settlement agreement.
- Excluding this one-off payment, underlying operating cash outflows improved through lower purchasing, reduced staff costs and continued cost control.

Financial Overview

Holista Colltech Limited (“Holista” or the “Company”) provides the following update for the quarter ended 30 June 2026. During the quarter, Group revenue remained broadly stable, customer receipts improved and the Company continued to manage costs while progressing the Ovicoll joint venture. The quarter was also significantly affected by the first tranche payment under the ProlImmune legal settlement agreement.

Customer receipts increased to approximately \$1.48 million, compared with \$1.31 million in the previous quarter. The increase mainly reflected improved collections

from sales of supplements generated in the previous quarter, debt recoveries of approximately \$21,000, and deposits of approximately \$67,000 received from a customer of its food ingredients.

Operating cash outflows increased during the quarter, primarily due to the first tranche payment of US\$1.0 million, equivalent to approximately \$1.44 million, relating to the ProImmune legal settlement. This contributed to a net operating cash outflow of \$1.29 million for the quarter, compared with \$155,000 in the previous quarter.

Excluding this one-off payment, underlying operating cash outflows improved compared with the previous quarter. This reflected lower inventory purchases, reduced staff costs following the transfer of employees to the joint venture company, and continued cost management.

Investing cash inflows of approximately \$88,000 primarily reflected the maturity and withdrawal of fixed deposits.


Financing activities resulted in a net cash outflow of \$170,000, reflecting movements in banker acceptances and scheduled term loan repayments.

Cash and cash equivalents at quarter end were \$526,000, down from \$1.94 million at the start of the quarter, primarily reflecting the ProImmune settlement payment. Including approximately \$1.45 million in unused financing facilities, total available funding at quarter end was approximately \$1.97 million.

Based on the current quarter's net operating cash outflow, this represents an estimated 1.53 quarters of funding, and further detail on the Company's funding plans is set out in the accompanying Appendix 4C.

The Company continues to closely monitor its cash position and will consider further capital management initiatives, including the unused facilities noted above and, where appropriate, additional capital raising, to support ongoing operations.

In accordance with ASX Listing Rule 4.7C, no payments were made to related parties or their associates during the quarter.




**FY2025 figures have been adjusted to audited figures.
FY2026 figures are subject to audit.*

Divisional Performance

Group revenue increased 0.8% to approximately \$1.50 million during the quarter. The Supplement segment continued to contribute the majority of Group revenue, while movements in the other segments were mainly affected by shipment timing.

- **Supplement:** Sales were approximately \$1.44 million, down 1.5% from the previous quarter.
- **Food Ingredients:** Sales increased to approximately \$19,000, compared with \$11,000 in the previous quarter, mainly due to shipment timing.
- **Ovine Collagen:** Sales of approximately \$29,000 were recorded during the quarter, compared with no sales in the previous quarter.
- **Infection Control / Agriculture:** Sales were approximately \$10,000, broadly consistent with the previous quarter.



**FY2025 figures have been adjusted to audited figures.
FY2026 figures are subject to audit.*

Corporate Update

1. ProlImmune Litigation

Following the Supreme Court of Western Australia judgment, the Company entered into a settlement agreement with ProlImmune Company LLC to fully and finally resolve the litigation for US\$1.8 million, payable in two instalments.

The first tranche of US\$1.0 million was paid on 22 April 2026 and was the main contributor to the operating cash outflow reported for the quarter. Subsequent to the quarter end, the Company paid the final settlement amount of US\$800,000 on 10 July 2026, completing its obligations under the settlement agreement.

2. Ovicoll Joint Venture

During the quarter, the Company continued to progress the establishment of Ovicoll Pty Ltd (“Ovicoll”), its 50:50 joint venture with Swang Chai Chuan Limited (“SCC”).

Following SCC's contribution of RM5.0 million, Ovicoll completed the acquisition of land in Collie, Western Australia, for the proposed collagen manufacturing facility. Planning and implementation activities remain ongoing, and further updates will be provided as material milestones are reached.

The Company remains focused on maintaining financial discipline, supporting its core businesses and progressing the Ovicoll project in a measured manner. While improvements were recorded in customer receipts and underlying operating cash flows during the quarter, the Group's recovery remains ongoing.

-ENDS-

About Holista Colltech Limited

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions. Operating across four dynamic business divisions—Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control/Agriculture Solutions—Holista delivers cutting-edge products that blend nature and science for healthier lifestyles.

Our portfolio features leading nutritional supplements, patented low-GI food ingredients, premium disease-free ovine collagen, and eco-friendly, non-toxic sanitizers for everyday and industrial use. We are dedicated to sustainable, science-driven solutions that empower better living and create lasting value for our stakeholders worldwide.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

HOLISTA COLLTECH LIMITED (ASX: HCT)

ABN

24 094 515 992

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	1,481	2,793
1.2	Payments for:		
	(a) research and development	(5)	(10)
	(b) product manufacturing and operating costs	(611)	(1,638)
	(c) advertising and marketing	(191)	(34)
	(d) leased assets	-	-
	(e) staff costs	(327)	(772)
	(f) administration and corporate costs	(172)	(279)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	11	11
1.5	Interest and other costs of finance paid	(20)	(46)
1.6	Income taxes paid	(17)	(31)
1.7	Government grants and tax incentives	-	-
1.8	Other (ProImmune legal settlement)	(1,436)	(1,436)
1.9	Net cash from / (used in) operating activities	(1,287)	(1,442)
2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from the disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) Investments	88	118
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	88	118
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	1,356	2,830
3.6	Repayment of borrowings	(1,526)	(3,054)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(170)	(224)
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,944	2,161
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,287)	(1,442)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	88	118
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(170)	(224)
4.5	Effect of movement in exchange rates on cash held	(49)	(87)
4.6	Cash and cash equivalents at end of period	526	526

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	526	856
5.2	Call deposits	-	1,088
5.3	Bank overdrafts	-	-
5.4	Other (Restricted Cash)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	526	1,944

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i> Fees include Salaries, Director Fees and Consulting Fees to Executive Director and Non-Executive Directors		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	414	414
7.2 Credit standby arrangements	2,325	877
7.3 Other (please specify)		
7.4 Total financing facilities	2,739	1,291
7.5 Unused financing facilities available at quarter end		1,448
7.6 Include in the box below a summary of each finance facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
Summary of Banking Facilities:		
<u>Bank Loan Facility 1:</u> Parties: CIMB Islamic Bank Berhad Malaysia (Banker), and Holista Biotech Sdn Bhd (100% subsidiary of Holista Collect Ltd) (Borrower). i) Loan Facility 1 Term Loan Principal Amount: MYR 1.4M / approximately A\$501K Remaining Payable as at 30 June 2026: MYR 1.1M / approximately A\$392K Term: Commencing on 1 October 2020 and repayable over 240 monthly instalments (principal plus interest) of \$3,114 (2025: \$3,204) and ending in 200 months on 4 October 2040. Interest Rate: 3.50% per annum (2025: 3.74%). ii) Credit Standby Arrangement 1 Trade Financing and Banker Acceptances bears interest of 4.83% per annum (2025: 4.83%). Total Amount at Quarter End: MYR 2M / Approximately A\$715K Total Utilised at Quarter End: MYR 1.174K / Approximately A\$420K Bank Loan Facility 1 is secured by the following: • Fixed deposit with a licensed bank of the Group and the Company; • Facility agreement; • First party assignment over the office lots of the Company; • Deed of assignment of rental proceeds; • Executed fresh letter of authorisation, memorandum of deposit and letter of off-set; and • Guarantee by a director of the Company. Bank Loan Facility 1 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes: • "Accepted Bills-i", to facilitate local and export sales of the Borrower; • "Multi Currency Trade Financing-i", to facilitate local and export sales of the Borrower; and • "Bank Guarantee", for issuance of financial, performance and security bonds to government and private entities, in relation to business.		

Bank Loan Facility 2:

Parties: CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

i) Loan Facility 2

Term Loan

Principal Amount: MYR 200K / approximately A\$71K.

Amount Remaining as at 30 June 2026: MYR 60K / approximately A\$21K

Term: Commencing on 28 September 2022 and repayable over 60 monthly instalments (principal plus interest) of A\$1,405 (2025: A\$1,423) and ending in 44 months on 4 November 2027.

Interest Rate: 3.68% per annum (2025: 3.68%).

ii) Credit Standby Arrangement 2

Trade Financing and Banker Acceptance bears interest of 4.83% per annum (2025: 5.19%).

Total Amount at Quarter End: MYR 1.5M / Approximately A\$537K

Total Utilised at Quarter End: MYR 1.277K / Approximately A\$457K

Bank Loan Facility 2 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company;
- Assignment of director insurance;
- Corporate guarantee; and
- Guarantee by a director of the Company.

Bank Loan Facility 2 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- “**Accepted Bills-i**”, to facilitate local and export sales of the Borrower;
- “**Multi Currency Trade Financing-i**”, to facilitate local and export sales of the Borrower;
- “**Documentary Credit-i**”, to facilitate local and import purchases of the Borrower;
- “**Accepted Bills-i 2**”, to facilitate local and import purchases of the Borrower; and
- “**Multi Currency Trade Financing-i 2**”, to facilitate local and import purchases of the Borrower.

Bank Loan Facility 3:

Parties: CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

i) Credit Standby Arrangement 3

Trade Financing and Banker Acceptance bears interest of 5.09% per annum.

Total Amount at Quarter End: MYR 3.0M / Approximately A\$1,073K

Total Utilised at Quarter End: nil

Bank Loan Facility 3 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company.

Bank Loan Facility 3 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- “**Accepted Bills-i**”, to facilitate local and export sales of the Borrower;
- “**Multi-Currency Trade Financing-i**”, to facilitate local and export sales of the Borrower;
- “**Documentary Credit-i**”, to facilitate local and import purchases of the Borrower;
- “**Accepted Bills-i 2**”, to facilitate local and import purchases of the Borrower; and
- “**Multi-Currency Trade Financing-i 2**”, to facilitate local and import purchases of the Borrower.

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,287)
8.2	Cash and cash equivalents at quarter end (item 4.6)	526
8.3	Unused finance facilities available at quarter end (item 7.5)	1,448
8.4	Total available funding (item 8.2 + item 8.3)	1,974
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	1.53
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: No. The Company does not expect the current level of net operating cash outflows to continue. The reported quarter included the first settlement payment of US\$1.0 million under the ProImmune litigation settlement. The final settlement payment of US\$800,000 will be made in Q2 FY2026. Following completion of these settlement payments, the Company expects net operating cash outflows to reduce thereafter, subject to normal operating and working capital requirements.	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: The Company currently has access to unused funding facilities totalling approximately \$1.448 million. It expects to meet its operating cash requirements through a combination of these facilities, existing working capital and, where appropriate, additional capital raising if required.	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: Yes. The Company expects to continue its operations and meet its business objectives based on the non-recurring nature of the ProImmune settlement payments referred to in section 8.6.1, together with the availability of unused funding facilities, existing working capital and ongoing management of operating cash flows.	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 July 2026

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.